NICE Decision On Arthritis Opens Door For Biosimilars

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

 
• By Dave Wallace

A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

Open Door Light
The NICE decision opens the door for biosimilars to treat more UK patients • Source: Alamy

More from Biosimilars

More from Products